Neovacs will partner with 3P Biopharmaceuticals to manufacture interferon alpha (IFNa) following its purchase of technology from AMEGABIOTECH.
“This partnership is in line with the recent license agreement signed with AMEGABIOTECH,” Neovacs CEO Miguel Sieler said. “The completion of these two steps allows us to secure the complete production chain for the manufacture of IFNa, one of the primary raw materials of our most advanced product, IFNa Kinoid. In addition, the agreement complements the partnership signed earlier this year with Stellar Biotechnologies, the supplier of the other main component of our vaccine IFNa Kinoid, Keyhole Limpet Hemocyanin."
Within the framework of this partnership, Stellar Biotechnologies holds 30 percent of Neostell, the production subsidiary of Neovacs.
Neovacs’ licensing agreement with AMEGABIOTECH will result in the direct transfer of the technology used to manufacture IFNa directly to 3P Biopharmaceuticals. The transfer of the technology directly to 3P will guarantee the manufacturing of the IFNa cytokine.
3P Biopharmaceuticals is the only Spanish manufacturer of biological products in the health care field.